CY1116234T1 - Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 - Google Patents

Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3

Info

Publication number
CY1116234T1
CY1116234T1 CY20151100390T CY151100390T CY1116234T1 CY 1116234 T1 CY1116234 T1 CY 1116234T1 CY 20151100390 T CY20151100390 T CY 20151100390T CY 151100390 T CY151100390 T CY 151100390T CY 1116234 T1 CY1116234 T1 CY 1116234T1
Authority
CY
Cyprus
Prior art keywords
carboxamides
substituted
kcnq2
conformers
quinoline
Prior art date
Application number
CY20151100390T
Other languages
English (en)
Inventor
Sven Kühnert
Gregor Bahrenberg
Achim Kless
Wolfgang Schröder
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1116234T1 publication Critical patent/CY1116234T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Η εφεύρεση αφορά σε υποκατεστημένα 2-οξυ-κινολινο-3-καρβοξαμίδια, σε φαρμακευτικές συνθέσεις που περιέχουν τις ενώσεις αυτές και επίσης στις ενώσεις αυτές για χρησιμοποίηση στη θεραπεία και/ή προφύλαξη πόνου και άλλων ασθενειών και/ή διαταραχών.
CY20151100390T 2010-08-27 2015-04-29 Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 CY1116234T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10008921 2010-08-27
EP11754833.9A EP2609083B1 (en) 2010-08-27 2011-08-26 Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators

Publications (1)

Publication Number Publication Date
CY1116234T1 true CY1116234T1 (el) 2017-02-08

Family

ID=43297040

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100390T CY1116234T1 (el) 2010-08-27 2015-04-29 Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3

Country Status (29)

Country Link
US (2) US8653101B2 (el)
EP (1) EP2609083B1 (el)
JP (1) JP5837933B2 (el)
KR (1) KR20130100300A (el)
CN (1) CN103068804B (el)
AR (1) AR082732A1 (el)
AU (1) AU2011295405B2 (el)
BR (1) BR112013004562A2 (el)
CA (1) CA2809341A1 (el)
CL (1) CL2013000520A1 (el)
CO (1) CO6700824A2 (el)
CY (1) CY1116234T1 (el)
DK (1) DK2609083T3 (el)
EC (1) ECSP13012453A (el)
ES (1) ES2537628T3 (el)
HK (1) HK1185347A1 (el)
HR (1) HRP20150526T1 (el)
IL (1) IL223885A (el)
MX (1) MX342119B (el)
NZ (1) NZ604745A (el)
PE (1) PE20131379A1 (el)
PL (1) PL2609083T3 (el)
PT (1) PT2609083E (el)
RS (1) RS54007B1 (el)
RU (1) RU2595894C2 (el)
SI (1) SI2609083T1 (el)
TW (1) TWI522349B (el)
WO (1) WO2012025236A1 (el)
ZA (1) ZA201302266B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54002B1 (en) * 2010-08-27 2015-10-30 Grünenthal GmbH SUBSTITUTED 2-OXO AND 2-THIOXO-DIHYDROCHINOLINE-3-CARBOXAMIDES AS KCNQ2 / 3 MODULATORS
CN103068804B (zh) * 2010-08-27 2015-08-19 格吕伦塔尔有限公司 作为kcnq2/3调节剂的取代的2-氧基-喹啉-3-甲酰胺
US9775843B2 (en) 2012-10-11 2017-10-03 Grünenthal GmbH Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
BR112015012418A2 (pt) 2012-11-28 2017-07-11 Gruenenthal Gmbh carboxamidas específicas como moduladores de kcnq2/3
EP2925759A1 (en) 2012-11-28 2015-10-07 Grünenthal GmbH Heteroquinoline-3-carboxamides as kcnq2/3 modulators
CA2912064A1 (en) 2013-05-16 2014-11-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds for inhibiting drug-resistant strains of hiv-1 integrase
US20230131535A1 (en) * 2019-10-07 2023-04-27 D. E. Shaw Research, Llc ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2513949A1 (de) 1975-03-29 1976-10-07 Bayer Ag Azofarbstoffe
DE2706977A1 (de) 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
FR2482596A1 (fr) 1980-05-19 1981-11-20 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament
DE3111934A1 (de) 1981-03-26 1982-10-07 Bayer Ag, 5090 Leverkusen Oel-in-wasser-emulsionen, verfahren zu deren herstellung und deren verwendung
FR2509728A1 (fr) 1981-07-17 1983-01-21 Roussel Uclaf Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
DE3210063A1 (de) 1982-03-19 1983-09-22 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
DE3211934A1 (de) 1982-03-31 1983-10-13 Hoechst Ag, 6230 Frankfurt Salicylsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
FR2532939A1 (fr) 1982-09-13 1984-03-16 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus
DE4032147A1 (de) 1990-10-10 1992-04-16 Bayer Ag Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung
US5359365A (en) 1991-05-24 1994-10-25 Canon Kabushiki Kaisha Moving image processing method and apparatus
US5525611A (en) 1993-06-04 1996-06-11 Behforouz; Mohammad Lavendamycin analogs and methods of making and using them
US6030983A (en) 1993-06-04 2000-02-29 Ball State University Lavendamycin analogs, quinoline-5,8-diones and methods of using them
EP0634169B1 (en) 1993-06-29 2000-01-05 Takeda Chemical Industries, Ltd. Quinoline or quinazoline derivatives and their use in the manufacture of a medicament for the treatment of osteoporosis
EP0716077A1 (de) 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
WO1996026925A1 (fr) 1995-03-01 1996-09-06 Banyu Pharmaceutical Co., Ltd. Derives de l'arylthioacetamide
DE19738616A1 (de) 1997-09-04 1999-03-11 Clariant Gmbh 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel
GB9807114D0 (en) 1998-04-02 1998-06-03 Smithkline Beecham Plc Novel process
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
US6248736B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
EP1147094A1 (en) 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
CA2378241A1 (en) 1999-08-04 2001-02-15 Icagen, Inc. Benzanilides as potassium channel openers
WO2001010381A2 (en) 1999-08-04 2001-02-15 Icagen, Inc. Methods for treating or preventing pain and anxiety
US6395750B1 (en) 1999-10-25 2002-05-28 Active Biotech Ab Drugs for the treatment of malignant tumors
CA2438868A1 (en) 2001-02-20 2002-09-19 Valentin K. Gribkoff Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
EP1361879A1 (en) 2001-02-20 2003-11-19 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
US6593349B2 (en) 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
WO2002081728A2 (en) 2001-04-06 2002-10-17 Smithkline Beecham Corporation Quinoline inhibitors of hyak1 and hyak3 kinases
CA2499213A1 (en) 2002-09-17 2004-04-01 Pharmacia Corporation Aromatic liver x-receptor modulators
EP1539767A4 (en) 2002-09-18 2006-07-19 Univ Missouri FOR THE DELTA OPIOID RECEPTOR SELECTIVE OPIATANALOGA
JP4652816B2 (ja) 2002-12-23 2011-03-16 アイシーエージェン インコーポレイテッド カリウムチャネルモジュレータとしてのキナゾリノン
EP1449841A1 (en) 2003-02-19 2004-08-25 Bayer CropScience SA New fungicidal compounds
WO2004083184A1 (ja) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited 受容体拮抗剤
CN1886393A (zh) 2003-10-08 2006-12-27 沃泰克斯药物股份有限公司 含有环烷基或吡喃基基团的atp－结合弹夹转运蛋白的调控剂
EP1689742B1 (en) 2003-11-24 2010-03-17 Pfizer, Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
AR048669A1 (es) 2004-03-03 2006-05-17 Syngenta Ltd Derivados biciclicos de bisamida
BRPI0510598A (pt) 2004-05-04 2007-11-20 Pfizer compostos de amida de aril ou heteroaril substituìdos
CA2585490A1 (en) 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
MX2007010547A (es) 2005-03-03 2007-10-03 Lundbeck & Co As H Derivados de piridina sustituidos.
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
WO2007015767A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company Pyridine derivatives as dipeptedyl peptidase inhibitors
WO2007030582A2 (en) 2005-09-09 2007-03-15 Bristol-Myers Squibb Company Acyclic ikur inhibitors
JP2009515934A (ja) 2005-11-18 2009-04-16 ノイロサーチ アクティーゼルスカブ 新規なキナゾリン誘導体及びこれらの医学的使用
US7728130B2 (en) 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
CA2935569A1 (en) 2006-04-13 2007-10-25 Teva Pharmaceuticals International Gmbh Transdermal methods and systems for the delivery of anti-migraine compounds
US7763607B2 (en) 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
US20120088746A1 (en) 2006-05-10 2012-04-12 Pfizer Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
CA2656875C (en) 2006-07-11 2011-09-06 Pfizer Inc. Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
US7872128B2 (en) 2006-07-20 2011-01-18 Amgen Inc. Benzisoxazole and isoxazolo-pyridine compounds and method of use
AU2007275683B2 (en) 2006-07-20 2012-05-10 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
AU2007276804A1 (en) 2006-07-26 2008-01-31 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
US20100022589A1 (en) 2006-07-27 2010-01-28 Mccoull William Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
US20110130397A1 (en) 2006-09-22 2011-06-02 Soongyu Choi Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
JP2010512305A (ja) 2006-10-23 2010-04-22 ファイザー株式会社 置換フェニルメチルビシクロカルボキシアミド化合物
WO2008097976A1 (en) 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
US9162984B2 (en) 2007-03-30 2015-10-20 University Of Rochester Small-molecule modulators of melanin expression
JP5408434B2 (ja) * 2007-07-03 2014-02-05 アステラス製薬株式会社 アミド化合物
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
WO2009019149A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
DE102007044277A1 (de) * 2007-09-17 2009-03-19 Grünenthal GmbH Substituierte Nicotinamid-Verbindungen und deren Verwendung in Arzneimitteln
US8299123B2 (en) 2007-10-19 2012-10-30 Boehringer Ingelheim International Gmbh CCR10 antagonists
US8119656B2 (en) 2007-12-07 2012-02-21 The Board Of Regents Of The University Of Texas System Inhibitors of the influenza virus non-structural 1 protein
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8513295B2 (en) 2008-09-23 2013-08-20 Georgetown University Viral and fungal inhibitors
CA2739740A1 (en) 2008-10-24 2010-04-29 Gruenenthal Gmbh Substituted 4,5,6,7-tetrahydrothienopyridines as kcnq2/3 modulators for treating pain, epilepsy and urinary incontinence
US8367700B2 (en) 2008-12-17 2013-02-05 Gruenenthal Gmbh Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators
WO2010094644A1 (en) 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2010094645A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
TWI504395B (zh) 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
BRPI1009428A2 (pt) 2009-03-10 2016-03-01 Gruenenthal Gmbh 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3
TWI461197B (zh) * 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
CA2805932A1 (en) * 2010-08-27 2012-03-01 Gruenenthal Gmbh Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
CN103068804B (zh) * 2010-08-27 2015-08-19 格吕伦塔尔有限公司 作为kcnq2/3调节剂的取代的2-氧基-喹啉-3-甲酰胺
TWI565465B (zh) 2010-08-27 2017-01-11 歌林達股份有限公司 作為ｋｃｎｑ２／３調節劑之被取代之喹啉－３－甲醯胺
RS54002B1 (en) * 2010-08-27 2015-10-30 Grünenthal GmbH SUBSTITUTED 2-OXO AND 2-THIOXO-DIHYDROCHINOLINE-3-CARBOXAMIDES AS KCNQ2 / 3 MODULATORS

Also Published As

Publication number Publication date
MX2013002118A (es) 2013-04-03
US20140080867A1 (en) 2014-03-20
US9073862B2 (en) 2015-07-07
TW201211006A (en) 2012-03-16
CN103068804B (zh) 2015-08-19
KR20130100300A (ko) 2013-09-10
AU2011295405B2 (en) 2015-01-22
CN103068804A (zh) 2013-04-24
ES2537628T3 (es) 2015-06-10
US8653101B2 (en) 2014-02-18
US20120053205A1 (en) 2012-03-01
RU2595894C2 (ru) 2016-08-27
NZ604745A (en) 2015-01-30
CL2013000520A1 (es) 2013-08-02
PE20131379A1 (es) 2013-11-29
WO2012025236A1 (en) 2012-03-01
DK2609083T3 (da) 2015-03-30
CA2809341A1 (en) 2012-03-01
HRP20150526T1 (hr) 2015-06-19
JP5837933B2 (ja) 2015-12-24
TWI522349B (zh) 2016-02-21
PT2609083E (pt) 2015-07-01
EP2609083A1 (en) 2013-07-03
PL2609083T3 (pl) 2015-07-31
ZA201302266B (en) 2016-02-24
MX342119B (es) 2016-09-14
AR082732A1 (es) 2012-12-26
BR112013004562A2 (pt) 2016-09-06
ECSP13012453A (es) 2013-03-28
CO6700824A2 (es) 2013-06-28
EP2609083B1 (en) 2015-02-25
IL223885A (en) 2016-05-31
RU2013113300A (ru) 2014-10-10
HK1185347A1 (en) 2014-02-14
SI2609083T1 (sl) 2015-04-30
RS54007B1 (en) 2015-10-30
AU2011295405A1 (en) 2013-01-10
JP2013536210A (ja) 2013-09-19

Similar Documents

Publication Publication Date Title
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
MX343687B (es) Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
EA201591166A1 (ru) Ингибиторы аутотаксина
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
CY1118542T1 (el) Φθορομεθυλ-υποκατεστημενα καρβοξαμιδια πυρρολιου
PH12015502365B1 (en) Bace1 inhibitors
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
EA201590562A1 (ru) Бензамиды
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
EA201391304A1 (ru) 2,4-замещенные пиримидиндиамины для применения при дискоидной волчанке
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.